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ABSTRACT 
 
Parkinson’s disease (PD) is a neurodegenerative disorder caused by both 
environmental and genetic factors. Ubiquitin carboxyl-terminal hydrolase L1 
(UCH-L1) genetic mutations have been implicated in PD pathogenesis, 
potentially due to changes in autophagy. Recent reports suggest that autophagy 
is not affected when mitochondrial UCH-L1 is inhibited, reflected by the 
autophagy marker, microtubule-associated protein 1 light chain 3, or LC3. 
However, these experiments discount the fact that autophagy is not static, but a 
dynamic cycle that must be measured appropriately (Cartier et al, 2012). Using 
this as the driving force of my study, I suppressed autophagy with the lysosomal 
inhibitor bafilomycin in addition to inhibiting UCH-L1. Using an insulinoma cell 
line, a neuroblastoma cell line, and primary neurons, I illustrate that LC3-II levels 
rise due to an increase in autophagic flux and not because of a decrease in 
autophagosome clearance. These findings also shed light on how UCH-L1 can 
be studied as a future target for PD prevention and treatment with respect to 
autophagy.  
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INTRODUCTION  
 
Mitochondrial Background   
Eukaryotic cells rely on functional mitochondria for many essential 
functions, ranging from calcium homeostasis to energy generation in the form of 
ATP. Mitochondria also play a role in cell death, evident by their storage of pro-
apoptotic molecules. Mitochondrial health is often measured by membrane 
potential; high membrane potential indicates healthy mitochondria, while a loss of 
membrane potential signals damaged mitochondria. Although the regulatory 
mechanisms are still largely unknown, neurons move active, healthy 
mitochondria in the anterograde direction, recruiting these organelles to regions 
of the cell with high-energy demands, such as presynaptic and postsynaptic 
sites.  Unhealthy, damaged mitochondria move in a retrograde direction, 
returning to the cell soma for repair or destruction (Twig et al, 2008, Vives-Bauza 
and Przedborski, 2011).  
 
Mitochondrial Dynamics 
Mitochondria undergo dynamic fission and fusion events, appropriately 
termed mitochondrial dynamics (Figure 1) (Twig et al, 2008, Vives-Bauza and 
Przedborski, 2011). Fission of the mitochondrial network is an important part of 
many cellular events including the differentiation of cells in post-mitotic states, 
autophagy, and cell death. Events that trigger fission include varying levels of 
intracellular calcium, changes in the membrane potential in mitochondria and the 
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adenosine triphosphate (ATP) availability (Kadenbach, 2012, Twig et al, 2008). 
Fusion occurs when the outer and/or inner membranes from two different 
mitochondria unite (Figure 1). Fusion events generate continuous mitochondrial 
networks and matrices, resulting in shared solutes, proteins and an 
electrochemical gradient.  
 
 
Figure 1 – Mitochondrial fusion and fission. Adapted from Seo A Y et al, 2010. 
 
Mitochondrial dynamics allow mitochondria to adapt to changing 
environmental demands and facilitate mitochondrial quality control. Quality 
control is defined as removing slightly dysfunctional mitochondria and 
maintaining a healthy population of these organelles to prevent the rest of the 
population from being damaged. For instance, fusion integrates damaged 
mitochondria into the active pool, suggesting that dysfunctional or depolarized 
Possible relationship between mitochondrial fusion, fission, biogenesis and degradation. 
Seo A Y et al. J Cell Sci 2010;123:2533-2542 
©2010 by The Company of Biologists Ltd 
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mitochondria have the ability to be “rescued” by a fusion mechanism, recovering 
their activity. (Twig et al, 2008, Vives-Bauza and Przedborski, 2011).  
On the other hand, fission following fusion usually produces an unequal 
division of mitochondrial units in terms of function. Fission events can produce 
daughter units with different membrane potentials, and mitochondria with 
reduced membrane potentials are less likely to re-fuse with subsequent 
mitochondria.  This crucial mechanism protects the mitochondrial network by 
isolating and targeting damaged mitochondria for elimination by autophagy 
(Kadenbach, 2012, Twig et al, 2008, Vives-Bauza and Przedborski, 2011).  
 
Autophagy Background   
Autophagy is a mechanism cells employ to sequester and degrade 
cytoplasmic components (Figure 2). Macroautophagy (which will simply be 
referred to as autophagy moving forward) is a type of autophagy that originates 
with a double-membraned structure, or phagophore, that morphs into an 
autophagosome (AP) (Las et al, 2011, Mizushima et al, 2010). This structure 
captures the undesirable material from the cytoplasm such as organelles, lipids 
and protein aggregates. The AP then fuses with a lysosome to form an 
autolysosome, allowing acidification and degradation of the cytoplasmic material 
as well as the inner membrane of the AP (Las et al, 2011, Mizushima et al, 
2010). The small molecules formed during degradation can then be delivered to 
the cytoplasm and recycled (Figure 2) (Mizushima et al, 2010). 
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Figure 2 – Autophagy cycle. Adapted from Mizushima et al, 2010. 
 
Autophagy can be induced by nutrient starvation in all organisms from 
yeast to mammals. Other triggers include stressors such as hypoxia, a reduction 
in energy, endoplasmic reticulum (ER) stress, high temperature, protein 
aggregopathies, pharmacological agents and high-density conditions. Autophagic 
suppression is associated with aging and disease such as neurodegenerative 
disorders (Mizushima et al, 2010).  
 
Measuring Autophagy  
Events that stimulate autophagy tend to increase the number of APs. 
However, the presence of increased numbers of APs does not always mean that 
there is an increase in autophagic activity. APs are intermediates in the dynamic 
autophagy cycle. Therefore, accumulation of these structures may represent 
autophagic induction or it may denote suppression of autophagy downstream of 
Leading Edge
Primer
Cell 140, February 5, 2010 ©2010 Elsevier Inc. 313
Introduction
The past decade has witnessed an explosion of research on a 
fundamental cell biology pathway called autophagy (Greek for 
“self-eating”). The discovery of evolutionarily conserved genes 
(initially identi!ed in yeast) that are required for autophagy has 
enabled scientists to uncover a vast array of homeostatic, 
developmental, and other physiological functions of autophagy. 
Moreover, increasing evidence suggests that the deregulation of 
autophagy may contribute to a broad spectrum of mammalian 
diseases (Levine and Kroemer, 2008; Mizushima et al., 2008). 
Consequently, there is a rapidly growing need among scientists to 
be able to accurately detect autophagy and to study its function in 
diverse biological processes, especially in mammalian systems.
Research in mammalian autophagy has been historically 
plagued by two major considerations. First, there has been 
the challenge of capturing a “dynamic process” with “static 
measurements,” and the inherent limitations associated with 
making biological inferences based on such measurements. 
Second, there has been the challenge of separating “form” 
from “function,” and avoiding the common pitfall of assign-
ing physiological functions to autophagy based on its detec-
tion (or lack thereof) in a given physiological setting. These 
two challenges likely underlie many of the misconceptions in 
our historical understanding of the functions of mammalian 
autophagy. For example, certain neurodegenerative and myo-
degenerative diseases were initially believed to result, at least 
Methods in Mammalian Autophagy Research
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Autophagy has been implicated in many physiological and pathological processes. Accordingly, 
there is a growing scientific need to accurately identify, quantify, and manipulate the process 
of autophagy. However, as autophagy involves dynamic and complicated processes, it is often 
analyzed incorrectly. In this Primer, we discuss methods to monitor autophagy and to modulate 
autophagic activity, with a primary focus on mammalian macroautophagy.
Figure 1. The Process of Macroautophagy
A portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the au-
tophagosome subsequently f ses with the lysos me, nd the internal material is d graded in the autolysosome. In y ast, autophagosomes are generated from 
the preautophagosomal structure (PAS), which has not yet been identi!ed in mammalian cells. A partial list of treatments and reagents that modulate autophagy 
are indicated. Notably, lithium may also inhibit autophagy through mTOR activation. Atg proteins that have thus far been identi!ed on isolation membranes 
include ULK1/2, Atg5, Beclin 1, LC3, Atg12, Atg13, Atg14, Atg16L1, FIP200, and Atg101.
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AP formation. As a result, the methods used to quantify APs must be carefully 
controlled for and analyzed to avoid misinterpretation (Las et al, 2011, Mizushima 
et al, 2010). For instance, increased APs are commonly found among dying cells, 
leading scientists in the past to believe that it was a cell death pathway. Studies 
now show that autophagy is a quality control mechanism, and it is actually 
capable of keeping cells alive during stressful situations (Kadenbach, 2012, 
Mizushima et al, 2010, Twig et al, 2008). 
Another flaw encountered when analyzing this process occurs when static 
measurements are used to capture this dynamic process. It was originally 
thought, for example, that some neurodegenerative diseases were caused by an 
increase in autophagy. This was based on microscopic visualization of 
intermediates found early in the pathway. After using more appropriate 
measurements, it is speculated that when early intermediates accumulate, they 
likely block the later stages of autophagy from taking place, and it is in fact the 
decreased clearance that caused these disorders to occur. For instance, 
activating autophagy should increase the numbers of all autophagic structures 
compared to basal levels. If any step upstream of autophagosome formation is 
blocked, all autophagic structures should be decreased. Conversely, if steps 
downstream of autophagosome formation are blocked, autophagosome 
formation should increase but autolysosomes and other downstream structures 
should decrease. In both of these situations, there is an increase in the number 
of autophagosomes, despite the fact that autophagy is only upregulated in one 
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scenario. Therefore, looking at AP formation alone is insufficient for estimating 
autophagic activity. The synthesis, delivery, and degradation of autophagic 
substrates, known as autophagic flux, is a more accurate indicator of autophagic 
activity than measuring the amount of autophagosomes alone (Figure 3) 
(Mizushima et al, 2010).  
To study autophagy, APs are commonly monitored by tracking 
microtubule-associated protein 1 light chain 3, or LC3. After nascent LC3 is 
synthesized, a glycine residue is added at the C-terminus, becoming LC3-I which 
resides in the cytoplasm (Mizushima et al, 2010, Vives-Bauza and Przedborski, 
2011).  
Upon autophagic stimulation, LC3-I is lipidated and recruited to the AP 
membrane (Las et al, 2011, Mizushima et al, 2010). This occurs through a 
ubiquitination-like, enzymatic reaction in which LC3-I is conjugated with 
phosphatidylethanolamine (PE) and subsequently turns into LC3-II. LC3-I resides 
in the cytoplasm only, but LC3-II is associated with the inner and outer 
membranes of the autophagosome, hence its value as an autophagy marker. 
After fusing with the lysosome, the LC3-II located on the outer membrane of the 
autolysosome either is cleaved or remains bound until it is released back into the 
cytosol. Lysosomal enzymes degrade the LC3-II located on the inner membrane 
of the cell (Mizushima et al, 2010). 
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Figure 3 – Autophagic suppression. Adapted from Mizushima et al, 2010.  
 
The molecular weight (MW) of LC3-I is 14 kilodaltons (kD). Due to the 
addition of PE, LC3-II has a MW of 16 kD. However, LC3-II migrates more 
quickly than LC3-I in sodium dodecyl sulfate polyacrylamide gel electrophoresis, 
or SDS-PAGE gels, due to the hydrophobic nature of LC3-II. This distinction is an 
important aspect of LC3 measurements to keep in mind when analyzing western 
blots (Mizushima et al, 2010). 
Cell 140, February 5, 2010 ©2010 Elsevier Inc. 315
scienti!c methods in autophagy research that reliably deter-
mine (1) whether autophagy is present, upregulated, or sup-
pressed in a given biological context and (2) whether (and how) 
basal autophagy and/or modi!ed autophagy contribute mech-
anistically to the physiological or pathophysiological process 
under investigation.
The execution of autophagy involves a set of evolutionarily 
conserved gene products, known as the Atg proteins, that are 
required for the formation of the isolation membrane and the 
autophagosome (herein referred to as the “autophagic machin-
ery”) (Table 1). The process of autophagosome formation 
involves two major steps: nucleation and elongation of the isola-
tion membrane. The ULK/Atg1 kinase complex, the autophagy-
speci!c PI3-kinase complex, and PI(3)P effectors and their 
related proteins are important for the nucleation step, whereas 
the Atg12- and LC3/Atg8-conjugation systems are important 
for the elongation step. In addition, other proteins required for 
autophagosome-lysosomal fusion, lysosomal acidi!cation, and 
lysosomal digestion, and regulatory signals that integrate envi-
ronmental cues with the autophagic machinery are involved in 
autophagy. Details of the molecular regulation and machinery 
of autophagy have been reviewed elsewhere (He and Klionsky, 
2009; Longatti and Tooze, 2009). In mammalian cells, most of the 
Atg proteins are observed on isolation membranes (e.g., ULK1/2, 
Atg13, FIP200, Atg101, Beclin 1, Atg14, LC3, Atg12, Atg16L1) but 
not on complete autophagosomes (Longatti and Tooze, 2009) 
(Figure 1, Table 1). To date, only microtubule-associated pro-
tein light chain 3 (LC3), a mammalian homolog of yeast Atg8, 
is known to exist on autophagosomes, and therefore, this pro-
tein serves as a widely used marker for autophagosomes (Fig-
ures 1 and 4) (Kabeya et al., 2000; Mizushima et al., 2004). The 
identi!cation of the autophagic machinery has greatly facilitated 
the detection of autophagy (through LC3-based biochemical 
and microscopic assays), as well as the ability to experimen-
tally manipulate the autophagy pathway (through knockout or 
knockdown of autophagy genes or the expression of dominant 
negative autophagy proteins). The autophagy pathway can also 
be manipulated with agents that regulate autophagosome for-
mation or subsequent degradation steps (Figure 1).
Monitoring Cellular Autophagic Activity
A common misconception is the notion that increased numbers 
of autophagosomes in cells invariably correspond to increased 
cellular autophagic activity. Given that the autophagosome is 
an intermediate structure in a dynamic pathway, the number of 
autophagosomes observed at any speci!c time point is a func-
tion of the balance between the rate of their generation and the 
rate of their conversion into autolysosomes. Thus, autophago-
some accumulation may represent either autophagy induction 
or, alternatively, suppression of steps in the autophagy path-
way downstream of autophagosome formation. For example, 
compared to basal levels of autophagy (Figure 3A), autophagy 
activation is expected to result in an increase in the numbers of 
all autophagic structures (i.e., isolation membranes, autopha-
gosomes, and autolysosomes) (Figure 3B). If any step upstream 
of autophagosome formation is blocked, the numbers of all 
autophagic structures are decreased (Figure 3C). In contrast, 
the blockade of any step downstream of autophagosome 
formation increases the number of autophagosomes while 
decreasing the number of autolysosomes (Figure 3D). Notably, 
in two physiologically opposite scenarios, autophagy activa-
tion (and increased autophagic degradation) (Figure 3B) and 
blockade of a downstream step in autophagy (and decreased 
autophagic degradation) (Figure 3D), there is an increase in the 
number of autophagosomes. Therefore, the simple determina-
tion of numbers of autophagosomes is insuf!cient for an over-
all estimation of autophagic activity. Rather, different methods 
often need to be used in concert to distinguish between basal 
levels of autophagy, induction of autophagy, suppression 
of upstream steps of autophagy, and suppression of down-
stream steps of autophagy. The term “autophagic "ux” is used 
to denote the dynamic process of autophagosome synthesis, 
delivery of autophagic substrates to the lysosome, and deg-
radation of autophagic substrates inside the lysosome and is 
Figure 3. Dynamic Regulation of Autophagy and Cellular 
 Acc mulation of Different Autophagic Structu es
Depicted are the relative amounts of isolation membrane (IM), autophago-
somes (AP), and autolysosomes (AL).
(A) Under normal conditions, basal autophagy occurs.
(B) When autophagy is induced, for example by starvation, there is an in-
crease in all types of autophagic structures.
(C) When autophagy is suppressed at any step upstream, none of the au-
tophagic structures are generated.
(D) When autophagy is suppressed at any step after complete closure of the 
autophagosome, only autophagosomes accumulate.
Autophagic "ux increases in (B), but decreases in (C) and (D).
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LC3-II measurements are also subject to the same challenges as 
microscopic quantification of APs. For example, some pharmacologic agents 
block lysosomal acidification by inhibiting proton pumps in the lysosome. As a 
result, LC3-II accumulates in the presence of these drugs because the 
autophagic turnover of LC3-II is blocked. In this case, static assessment of LC3-II 
would appear to demonstrate an increase in autophagic stimulation.  The amount 
of LC3-II or AP number at one time point is not sufficient to make an assessment 
of autophagic activity. When LC3-II is degraded by autophagy, the decrease of 
total LC3 is paradoxically indicative of autophagic flux. Although LC3-II increases 
immediately upon autophagic induction, it decreases after autophagy has been 
activated for longer periods of time (Mizushima et al, 2010).  
Several substrates are preferentially degraded by autophagy, including the 
substrate p62, SQSTM1 or sequestome 1. The protein p62 is incorporated into 
APs by directly binding to LC3-II and then degraded in the autolysosome (Figure 
5). Therefore, the total cellular expression levels of p62 inversely correlate with 
autophagic activity, similar to LC3-II. Limitation to this interpretation include p62 
may be degraded by pathways other than autophagy and altered expression of 
p62. Both p62 and LC3 are regulated on a transcriptional level during autophagy, 
which confounds interpretation of p62 and LC3 levels as indicators of autophagic 
flux (Mizushima et al, 2010, Kadenbach, 2012). 
Another method used to track autophagic activity is to express the LC3 
protein fused with green fluorescent protein (GFP). GFP-LC3 is partially 
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degraded in the lysosome, which causes GFP to appear as a free fragment. GFP 
is a stably folded protein and is resistant to the protease action found in 
lysosomes, but the acidic enzymes found in the lysosome quench its fluorescent 
signal. However, this protein can still be detected by immunoblotting, and it is 
also more stable than GFP-LC3. (Figure 4). An increase in autophagic flux would 
therefore lead to an increase in lysosomal enzyme activity and an increase in 
free GFP. So probing for free GFP that has been generated from the degradation 
of GFP-LC3 in the autolysosome with an anti-GFP antibody aids in determining 
autophagic flux (Mizushima et al, 2010). 
 
Figure 4 – GFP cleavage from LC3. Adapted from Las et al, 2011.  
  
Parkinson’s Disease  
Dopaminergic neurons also tend to accumulate large amounts of 
mitochondrial DNA (mtDNA), possibly due to their high calcium conductance. As 
a result of the work of the fusion/fission machinery, the amount of mtDNA 
molecules carrying deletions in each mitochondrion is kept to a minimum. 
Parkinson’s disease (PD) is a neurodegenerative disorder affecting 1% of 
the United States population over 60. Symptoms are often characterized by 
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motor dysfunctions including rigidity, bradykinesia, resting tremor and postural 
instability as well as dementia. Although the cause of PD is unknown, a requisite 
neurophathological feature of PD is the loss of dopamine-containing neurons in 
the substantia nigra pars compacta (SNpc), causing a reduction of dopamine in 
the striatum. Proteinaceaous cytoplasmic inclusions, known as Lewy bodies, are 
also a requisite feature of PD and found in the surviving dopaminergic neurons. 
Alpha-synuclein (a-syn) and ubiquitin are prominent and defining components of 
Lewy bodies (Cartier et al, 2012, Vives-Bauza and Przedborski, 2011).  
Despite the unknown origin of PD, genetics and environmental factors are 
believed to cause events such as mitochondrial dysfunction, oxidative stress, and 
protein degradation machinery failure, leading to the demise of SNpc 
dopaminergic neurons. A defect in autophagy, especially autophagy in 
mitochondria, known as mitophagy, has emerged as a leading pathogenic 
hypothesis in the PD field. Damaged mitochondria are normally cleared from 
cells, but malfunction in PD-linked proteins may bring about neurodegeneration 
by causing defects in a quality control mechanisms such as mitophagy (Vives-
Bauza and Przedborski, 2011). 
There are both sporadic and familial forms of PD, and two genetic factors 
associated with the inherited form of PD are Parkin and phosphatase and tensin 
homolog-induced putative kinase-1, or PTEN-induced putative kinase-1, or 
PINK1. Healthy mitochondria regularly import PINK1 and the protein is 
immediately cleaved and degraded once it enters the mitochondria. However, 
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when a mitochondrion is damaged and loses its membrane potential, PINK1 is 
not degraded. Increased localized functional PINK1 upregulates a signal cascade 
that activates mitophagy (Figure 5).  
 
 
Figure 5 – PINK1/Parkin signaling pathway with possible interactions with UCH-L1. Adapted from 
Vives-Bauza and Przedborski, 2011. 
 
Mitochondria-associated PINK1 recruits cytosolic Parkin when 
mitochondria are depolarized, triggering large clusters of mitochondria decorated 
with Parkin to assemble in lysosome-rich perinuclear areas of the cell. Parkin is 
an E3 ubiquitin ligases that adds polyubiquitin chains to the voltage-dependent 
anion channel 1, VDAC1 also known as porin, as well as outer membrane 
mitochondrial fusion proteins, Mfn (Figure 5). Parkin then recruits the adaptor 
proteins HDAC6 (ubiquitin-binding protein histone deacetylase 6) and p62 to the 
Mitophagy$$
other organelles such as peroxisomes [22,23]. Atg32 links
mitochondria to the autophagy machinery via interaction
with the core protein Atg8 and with Atg11, a yeast adaptor
protein for selective autophagy [24]. Thus far, no mammali-
an Atg32 homolog has been discovered, but several of the
Atg32 structural characteristics have pointed to the mam-
malian mitophagy factor Nix/BNIP3L [25] as a potential
candidate. Indeed, Nix, which is a noncanonical BH3 mem-
ber of the Bcl-2 family of proteins, like Atg32, is an outer
mitochondrial membrane protein that binds Atg8 and is
essential for mitochondrial destruction [26–29]. However,
despite the fact thatNix seems to be ubiquitously expressed
in mammals, up to now its role in mitophagy has only been
documented in the hematopoietic system during the matu-
ration of reticulocytes in erythrocytes [26–29].
Familial forms of PD point to a relation between PD and
mitophagy
PD commonly arises sporadically but, in some cases, the
disease is inherited. PARK6/PINK1 is one of the gene
products associated with familial PD [30,31]. This 581-
amino acid polypeptide is a serine/threonine kinase with a
high degree of homology to the Ca2+/calmodulin kinase
family that localizes to mitochondria. Loss-of-function
mutations in the gene encoding PARK2/Parkin (an E3
ubiquitin ligase) can cause an autosomal recessive form
of familial PD [31,32]. Drosophila carrying pink1 muta-
tions exhibit an abnormal mitochondrial morphology
[33,34]. In Drosophila, Parkin is thought to operate within
the same molecular pathway as PINK1 [33–35]. Although
the initial interpretation of these observations in Drosoph-
ila was that the PINK1/Parkin pathway modulates mito-
chondrial dynamics, mounting evidence, from primarily
mammalian cells, indicates that this pathway might in
fact modulate mitophagy [4–6,36,37]. These hypotheses,
however, are not mutually exclusive because fusion/fission
affects mitochondrial turnover by autophagy.
To our knowledge, the first experimental evidence sup-
porting a role for the Parkin in mitophagy originated from
the work of Narendra and collaborators [36]. These inves-
tigators found that Parkin, in both HEK293 and HeLa
cells, is selectively recruited through an unknown mecha-
nism to depolarized mitochondria, and is followed by a
profound mitochondrial disappearance in cultured cell
lines [36]. Within 48 h of exposure to the protonophore
m-chlorophenylhydrazone (CCCP), which collapses the
DCm, mitochondrial markers such as Tom20, cytochrome
c and TRAP1 (tumor necrosis factor type 1 receptor-asso-
ciated protein-1) were all lost, suggesting that mitochon-
dria were eliminated (Figure 1). The specificity of
mitochondrial elimination was remarkable because per-
oxisomes remained intact. Narendra and colleagues [36]
also provided data supporting the idea that depolarized
mitochondria were eliminated by autophagy. Indeed, mi-
tochondria were seen within intracellular LC3-positive
vesicular structures. In addition, they showed that
CCCP-triggered mitochondrial disappearance was abro-
gated in HeLa cells treated with the lysosomal inhibitor
bafilomycin A1 and inmutantmouse embryonic fibroblasts
(MEFs) deficient in the autophagic factor Atg5.
Do PINK1 and Parkin modify each other?
Parkin translocation to mitochondria relies on PINK1
expression (Figure 1), and if wild type but not functionally
deficient mutated PINK1 is overexpressed, Parkin can be
recruited to mitochondria with normal DCm [4–6,37]. The
la ter bse vat on suggests that PINK1, proba ly through
its kinase activity, is a key signalingmolecule inmitophagy
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Figure 1. The PINK1/Parkin signaling pathway. Damaged mitochondria lose their membrane potential, which inhibits PINK1 cleavage. The mitochondrial content of full-
length PINK1 thereby increases, which enhances PINK1 signaling. By an unknown mechanism, this triggers either directly or indirectly (a) Parkin recruitment to
mitochondria. (b) VDAC1 and/or MFN are ubiquitinated in a Parkin-dependent manner. Then, mitochondrial aggregation occurs because of the Parkin-mediated
ubiquitination of mitochondrial outer membrane proteins. (c) Both p62 and HDAC6 link polyubiquitinated mitochondria with LC3, initiating mitophagy.
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ubiquitinated proteins. HDAC6 and p62 then serve as the link between these 
ubiquitinated substrates and lipidated LC3, facilitating mitophagy through AP 
formation (Vives-Bauza and Przedborski, 2011). 
 
 Ubiquitin Proteasomal System  
As seen in Figures 5 and 6, eukaryotic cells use covalent ubiquitin (Ub) 
linkages, either through a single Ub moiety or a multi-Ub chain, to signal different 
cellular processes. Ligating a Ub monomer to a substrate occurs by forming an 
isopeptide bond between the ubiquitin’s C-terminal glycine residue and the 
substrate’s lysine, Lys, or K side chain of an amino group. Substrates with more 
than three Ub moieties via K48 linkages are targeted for degradation. 
Conjugation of a single Ub moiety or the ligation of a K63 ubiquitin chain signals 
membrane proteins to be endocytosed and protein sorting and trafficking to 
occur, promoting recycling or lysosomal degradation (Doss-Pepe et al, 2005).   
Parkin is a Ub ligase, playing a role in recognizing and ubiquitinating 
substrates. Doss-Pepe et al proposes that an altered assembly or recognition of 
K63 chains may result in errors in the turnover of neuronal cell surface proteins 
through the endocytic pathway and could underlie an important biochemical 
defect in PD (2005).  
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UCH-L1  
 
Figure 6 – Proposed functions of UCH-L1. Adapted from Hand, J, 2010.  
 
In addition to PINK1 and Parkin there are thirteen other genes that are 
linked to familial PD (Satake et al, 2009). Another PD gene connected to 
ubiquitination is ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1). UCH-L1 is 
highly abundant in neurons and the ubiquitin regulator comprises 1-2% of total 
brain protein (Cartier et al, 2012, Liu et al, 2009, Park et al, 2011). UCH-L1 is a 
cysteine protease that hydrolyzes poly-ubiquitin chains by hydrolyzing amide, 
ester and thioester bonds at the K48 sites, generating free Ub monomers. When 
dimerized, UCH-L1 ligates Ub monomers by forming a new chemical bond 
between the C-terminus of Ub with K63 of the other Ub, inhibiting degradation of 
mono-ubiquitin. While both of UCH-L1’s roles are important cellular processes, 
the conjugation of ubiquitin via K63 sites is critical for the study of autophagy in 
the context of PD because it is the form thought to be recognized by HDAC6 and 
p62 (Cartier et al, 2012, Park et al, 2011).    
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An I93M mutation in the UCH-L1 gene that presented decreased 
hydrolase activity in vitro was reported in a German family with autosomal 
dominant PD. The mutation illustrates that a loss of function in UCH-L1 may 
cause less available free ubiquitin and halt regular protein clearance. Transgenic 
(tg) mice that overexpressed the same I93M mutant also displayed behavioral 
and pathological characteristics similar to Parkinson’s (Cartier et al, 2012).  
Many studies have shown that UCH-L1 may play a role in regulating the 
balance between cell death and survival, but the mechanisms that regulates the 
UCH-L1 protein levels as well as its enzymatic activity still remain unclear. One 
study showed that inhibiting the hydrolase activity of UCH-L1 in primary neurons 
induced aggregation of ubiquitin-conjugated proteins, leading to an increase in 
cell death. Another study demonstrated that LDN-57444, a UCH-L1 inhibitor, is 
associated with cell death via ER-stress mediated accumulation of ubiquitinated 
proteins in neuroblastoma cells (Park et al, 2011). Another study by Bifsha et al 
found that in different lysosomal disorders and in a mouse-modeled brain 
disorder, UCH-L1 was downregulated. Their results demonstrated that 
suppressing lysosomal catabolism lead to secondary deficiency of UCH-L1, and 
directly downregulating UCH-L1 induced caspase-mediated apoptosis (2007). 
Both of these experiments illustrate that UCH-L1 deficiency leads to cell death 
and impairs the Ub-dependent protein degradation pathway (Bifsha et al, 2007 
and Park et al, 2011).  
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Another recent study investigated UCH-L1’s role in an apoptotic pathway 
and showed that in combination with other proteins, UCH-L1’s enzymatic 
reaction regulates cell death when it is induced by loss-of-UCH-L1 function (Park 
et al, 2011). All of these studies illustrate the importance of UCH-L1 regarding 
cell death and cell survival. UCH-L1, in combination with Parkin and alpha-
synuclein, has the ability to function with other enzymes and assemble Ub-K63 
chains, and may therefore all be genetically linked to PD (Doss-Pepe et al, 
2005).  
 Previous reports suggest that alpha-synuclein (a-syn) and UCH-L1 
interact. Liu et al, for example, demonstrated that membrane-associated UCH-L1 
that has been farnesylated promotes a-syn neurotoxicity. They hypothesized that 
the underlying mechanism of UCH-L1 and accumulation and neurotoxicity of a-
syn may involve chaperone-mediated autophagy (2009). Cartier et al studies 
UCH-L1 inhibition in the context of PD. Previously, Cartier et al showed that 
inhibiting UCH-L1 activity dysregulates monomeric ubiquitin homeostasis and 
alters synapse structure. In a continuation of this work, Cartier et al illustrates 
that inhibiting UCH-L1 activity has differential effects on a-syn distribution and 
protein expression levels in a-syn tg mice versus non-tg hippocampal tissues as 
well as primary neurons. Suppressing UCH-L1 activity increased a-syn levels in 
control and non-tg neurons, and also allowed a-syn to accumulate in the 
presynaptic vesicles of the neurons. Pharmacologically suppressing UCH-L1 
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activity in a-syn overexpressing neurons, however, decreased a-syn levels and 
enhanced its synaptic clearance (Cartier et al, 2012).  
Cartier et al verifies that suppressing UCH-L1 activity has a minimal effect 
on the autophagy marker, LC3, in control cells, and increases LC3 activity in cells 
overexpressing a-syn. The alterations of a-syn distribution correlated with 
alterations in the autophagy pathway in a-syn tg mice, leading them to believe 
that UCH-L1 functions differently under normal and pathological conditions 
(Cartier et al, 2012).  
 
 
Figure 7 – The actions of UCH-L1 and bafilomycin. Adapted from Lu et al, 2011.  
 
Cartier et al measures the autophagic marker LC3 in the presence of a 
UCH-L1 inhibitor, but takes does not take into account the fact that autophagy is 
a dynamic process (2012). Inhibiting UCH-L1 only does not accurately represent 
autophagic flux, and an increase in LC3 may actually reflect a decrease in 
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mitochondrial clearance, depending on the part of the autophagic cycle that is 
blocked. For instance, UCH-L1  may act towards the initiation portion of 
autophagy. Working upstream of autophagosome formation, UCH-L1 would 
activate autophagy. Therefore, inhibiting UCH-L1 would inhibit mitophagy. If 
UCH-L1 functions downstream of AP formation, however, during the acidifcation 
and degradation stages, this would inhibit mitophagy, and inhibiting UCH-L1 in 
this context would upregulate mitophagy (Mizushima et al, 2010). As a result, 
Cartier et al’s results may be incomplete or inaccurate (2012). Using this as an 
impetus for my project, I blocked autophagic flux with the lysosomal inhibitor, 
bafilomycin. This pharmacologic agent inhibits proton pumps on the lysosome, 
blocking AP maturation, acidification, and degradation (Mizushima et al, 2010).  
I hypothesized that without using bafilomycin, there would be no difference 
in LC3 levels in the presence of a UCH-L1 inhibitor, just as Cartier et al found 
(2012). However, I believed that using bafilomycin in addition to a UCH-L1 
inhibitor would increase the levels of LC3, causing an increase in autophagic flux. 
If LC3 levels decreased in the presence of bafilomycin and a UCH-L1 inhibitor, 
that would signify that mitochondrial clearance is decreased (Mizushima et al, 
2010).  
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SPECIFIC AIMS 
 
In cell models of Parkinson’s Disease, Cartier et al demonstrated that 
inhibiting UCH-L1 activity has only a minor effect on the autophagy marker, LC3 
in control cells, while increasing LC3 activity in cells overexpressing alpha-
synuclein. However, autophagy is a dynamic cycle, a fact that Cartier et al and 
many other studies failed to take into consideration. If analyzing LC3 activity as a 
result of UCH-L1 inhibition is done properly, will Cartier et al’s conclusions about 
autophagy still remain true (2012)?  
The goal of the present study is to analyze mitophagy with respect to PD 
by looking at the autophagy marker, LC3. In addition to using a UCH-L1 inhibitor, 
we will also block autophagy with the lysosomal inhibitor, bafilomycin. We will 
then use the results to determine if blocking UCH-L1 gives results comparable to 
Cartier et al’s, if it causes an increase in autophagic flux, or if mitochondrial 
clearance is decreased (Cartier et al, 2012 and Mizushima et al, 2010).  
We hypothesize that LC3 levels will be increased when UCH-L1 inhibitor 
and bafilomycin are used in conjunction. They will most likely be increased due to 
an increase in mitophagy. By carrying out this study, we aim to further clarify the 
mechanisms involved in mitophagy with respect to PD.  
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METHODS 
 
Reagents 
The following reagents were used: UCH-L1 inhibitor was purchased from 
Calbiochem (EMD Millipore) (Billerica,MA). Bafilomycin was purchased from LC 
Laboratories (Woburn, MA). Mitotracker® Green FM (Fluorescence Microscope), 
dimethyl sulfoxide (DMSO), and rotenone were all purchased from Invitrogen 
(Grand Island, NY).  
 
Cell Culture – 12 Well Plates and 96 Well Plates  
INS-1 cells are a rat insulinoma cell line and SH-SY5Y cells are a human 
neuroblastoma cell line. Both were taken from frozen vials in the Shirihai lab. 
LC3-GFP INS-1 cells were generated by Dr. Guy Las. Using a lenti-viral 
transduction, Andrew Ferree generated the constituitively expressing DsRed 
(discosoma red) SH-SY5Y cell line. LC3-GFP INS-1 cells and INS-1 cells without 
added constructs were cultured in Roswell Park Memorial Institute (RPMI) 1640 
(1X) media with [+] L-Glutamine, supplemented with 10% fetal bovine serum, or 
FBS, 10 mM 4-(2-hydroxyethyl)-1-piperaineethanesulfonic acid, or HEPES 
buffer, 1mM sodium pyruvate, 50 µM 2-B-mercaptoethanol, 50 units/milliliter, or 
50 unites/mL penicillin, and 50 micrograms/mL streptomycin. SH-SY5Y cells, 
DsRed SH-SY5Y cells, and mouse hippocampal neurons were all cultured in F12 
media supplemented with 15% FBS with glutamax and penstrep. Neuronal cells 
isolated from mouse hippocampal neurons were cultured in F12 media 
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supplemented with 50 units/mL penicillin. One group of neurons was cultured for 
fourteen days in vitro (DIV 14) and this was called trial 1, while another group of 
neurons was cultured in vitro for seven days (DIV 7) and this was called trial 2. 
The cells were all cultured at 37 degrees Celsius and had a constant supply of 
five percent carbon dioxide. All of the cell culture media and reagents were 
purchased from GIBCO (Grand Island, NY).   
 
Western Blot  
Cell lysates were homogenized in RIPA (Radio Immunoprecipitation 
Assay) buffer and protease inhibitor was added to the RIPA buffer at a 
concentration of 1:100. Cellular homogenates were centrifuged at 12000 rpm 
(revolutions per minute) for ten minutes and supernatants were removed and 
protein concentration was determined with a ThermoScientific protein assay kit 
using bovine serum albumin as a standard (Rockford, IL). Protein samples were 
resolved by 12% polyacrylamide SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) gel and electrophoretically transferred using 
a wet transfer method to nitrocellulose membranes from ThermoScientific 
(Rockford,IL). Membranes were then blocked for one hour in phosphate buffered 
saline with tween (PBST) blocking buffer (PBS, .1% Tween 20, and 5% milk) at 
room temperature and then incubated with primary antibodies in blocking buffer 
overnight at four degrees Celsius. The antibodies used were at the following 
dilutions: rabbit anti-cleaved LC3 (1:1000), rabbit anti- β-actin (1:2000), mouse 
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anti-p62 (1:2500), rabbit anti-glyceraldehyde 3-phosphate dehydrogenase, or 
rabbit anti-GAPDH (1:2000) and rabbit anti-GFP (anti-green fluorescent protein) 
(1:2000). The next day the membranes were washed three times for ten minutes 
each in PBST washing buffer (PBS, 0.1% Tween 20) and incubated with 
secondary antibodies in blocking buffer for one hour with anti-rabbit (1:10000) or 
anti-mouse (1:1000) antibodies conjugated to horseradish peroxidase. Blots were 
then washed again in PBST washing buffer three times for ten minutes each. 
Protein bands were visualized using a Chemiluminescence plus reagent 
(ThermoScientific, Rockford, IL) and a FujiFilm imager. The bands were digitized 
and quantified using NIH ImageJ software.  
 
FujiFilm Imaging 
The LAS-4000 Luminescent Image Analyzer is made by FujiFilm. It is a 
charge-coupled device, or CCD, camera system. It captures sensitive and 
quantitative images, and I used it to capture chemiluminescent images of 
Western blots. The frequency with which images were taken was set to every ten 
seconds, and the band strength was added to each past exposure. Using these 
settings allowed for optimal visualization and avoided saturation.   
 
ImageJ Software  
ImageJ is a Java processing image program that was used to digitize and 
quantify chemiluminescent bands on Western blots captured by the LAS-4000 
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analyzer. An area around the band of interest was selected and the same area 
was applied to each band on a single blot. Graphs of the bands were then 
generated, and the area under the curve was converted into a number that could 
be analyzed in the Microsoft program Excel. The numbers were normalized to a 
control band on each blot, either actin or GAPDH, so that the analysis was not 
effected by editing of the image.  
 
Celigo® Imaging  
Data on cells cultured in 96 well plates was acquired using Celigo® S. 
Celigo® is a cytometer that uses high-speed multi-channel brightfield and 
fluorescence imaging. This kind of imaging is used for high throughput whole well 
cellular image acquisition and is able to process multi-well plates.  
A 96 well BD Falcon 353219 plate was used in the Celigo® imager. We 
scanned the data by selecting Target 1 +2 (merge) in the expression analysis. 
Target 1 was set to the brightfield channel that imaged whole cells and target 2 
was set to the fluorescent scanner that imaged DsRed, GFP, or MitoTracker 
Green within each cell. Exposure time was autocalculated, and this was applied 
to all cells. However, if the intensity was saturated, exposure time was reduced 
so that approximately 90% of the cells were below saturation level. Focus type 
was image-based autofocus and the focus mode was set to fine and 
autoregistered.  
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To analyze the Celigo® data, Target 1 was set to auto-analyze because 
the brightfield data was not the main point of analysis. Target 2 had an intensity 
threshold of one, and the cell diameter was set to be a minimum of 30. Touching 
objects were separated, and cell area was set to a minimum of 100 to exclude 
small cell fragments and debris. Cell intensity was set to a minimum of 150 to 
exclude dim fragments and debris as well. Data was then taken from the average 
Target 2 integrated intensity. This is the average immunofluorescence of each 
cell based on the number of pixels. 
 
Trouble Shooting and Optimization Protocol 
The experimental protocol used to acquire the final results was 
continuously refined and improved based on cell response and the data 
obtained. For instance, SH-SY5Y cells were originally grown in media that did not 
support their development or life cycle. We changed the media from Dulbecco’s 
Modified Eagle Medium, or DMEM (Invitrogen, Grand Island, NY) to F12 media 
and increased the amount of FBS from 10% to 15%. These changes kept the 
SH-SY5Y cells alive for longer lengths of time than they originally lived, but the 
cells still died on a triweekly to monthly basis for unknown reasons.  
INS-1 cells grew rather well and did not die spontaneously as the SH-
SY5Y cells did, but there were problems with the amount of carbon dioxide in the 
cell incubator running out. As a result, the INS-1 cells died on four separate 
occasions. Each time was we had to begin the experiment again.  
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Knowing what concentrations of drugs to treat the cells with was also a 
critical portion of the experiment. Different concentrations of bafilomycin, 
rotenone, and UCH-L1 inhibitor were tested so that the amount of each 
pharmacological agent was correct. Cell confluence conditions were also tested 
because having too few or too many cells in a flask or well also resulted in cell 
death.  
Running western blots also came with unforeseen challenges. The very 
first western blots were ran on INS-1 cells, and worked well except for the fact 
that the LC3 was saturated in the image. Working to remedy this problem with 
different concentrations of chemiluminescent substrates, secondary antibodies 
and primary antibodies did not result in any useful changes. After repeated 
attempts at changing the antibodies concentrations without changes in the 
bands, the original blot was abandoned and a new gel was ran on a different 
group of cells.  
The next batch of western blots did not have problems with the gel but the 
transfers did not occur. It was later concluded that this was because the transfer 
buffer had expired. These gels were not able to be salvaged, so new cells were 
cultured, new cell lysates were made, and new gels were ran again. In the next 
set of gels, the transfer occurred but the results were not able to be visualized. 
The LAS-4000 FujiFilm imager and overnight photographic development were 
used. Both methods did not work, so new gels with new samples were run again, 
and these are the blots used for the current study.  
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RESULTS  
 
Celigo® Results  
SH-SY5Y cells were treated with a mitochondria label, MitoTracker Green, 
and plated in a 96 well BD Falcon 353219 plate. These were plated in 6 different 
rows and the fluorescence intensity was averaged between the wells in each 
row. Each row was treated with either 0, 1, or 10 µM UCH-L1 inhibitor. Half of the 
rows were treated with 300 µM rotenone, a cell stressor that induces cell death. 
Dimethyl sulfoxide, or DMSO, was used as a control, since the rotenone was 
dissolved in DMSO. Average fluorescence from each condition was normalized 
to the DMSO condition unless otherwise specified. As seen in Figure 9, 
MitoTracker Green cells treated with an increased amount of UCH-L1 inhibitor 
has less fluorescence. The cells treated with rotenone had on average less 
MitoTracker Green present than the cells without rotenone exposure in Figure 9. 
Figure 8 shows a slightly different pattern with larger error bars and more 
variation, so it will not be addressed in detail when discussion the results. 
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Figure 8 – Mitochondrial mass (MitoTracker Green) in SH-SY5Y cells treated with UCH-L1 
inhibitor and rotenone – Celigo® plate 1. 
 
 
 
Figure 9 – Mitochondrial mass (MitoTracker Green) in SH-SY5Y cells treated with UCH-L1 
inhibitor and rotenone – Celigo® plate 2.  
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SH-SY5Y cells transfected with DsRed were also treated with UCH-L1 
inhibitor and rotenone in the same experimental design as the SH-SY5Y cells 
labeled with MitoTracker Green. Figures 10 and 11 show that in the presence of 
UCH-L1 inhibitor, the average fluorescence intensity increases. Rotenone 
treatment alone increases average fluorescence intensity compared with the 
control group, but when UCH-L1 inhibitor is added to rotenone treatment, the 
average fluorescence intensity decreases. DsRed cells treated with bafilomycin 
in addition to UCH-L1 show an increase in average fluorescence intensity (Figure 
12).   
 
  
Figure 10 – Mitochondrial mass (matrix DsRed) in SH-SY5Y cells treated with UCH-L1 inhibitor 
and rotenone – Celigo® plate 3.  
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Figure 11 – Mitochondrial mass (matrix DsRed) in SH-SY5Y cells treated with UCH-L1 inhibitor 
and rotenone – Celigo® plate 4.  
 
 
 
 
Figure 12 Mitochondrial mass (matrix DsRed) in SH-SY5Y cells treated with UCH-L1 inhibitor and 
bafilomycin – Celigo® plate 5.  
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Western Blot Results  
INS-1 cells were plated and cultured in 12-well plates and treated with 
UCH-L1 inhibitor for 24 hours at concentrations of 0 µM, 1 µM, or 10 µM. Each of 
these groups was then treated with 200 nanomoles (nM) of the lysosomal 
inhibitor, bafilomycin, for 0 hours, 3 hours, or 6 hours before harvesting the cells 
for western blots. UCH-L1 inhibitor was used to affect autophagy, and the UCH-
L1treatment conditions chosen for my experiment were similar to Cartier et al’s 
(2012). However, I enhanced my experimental design by adding the 200 nM 
bafilomyin to inhibit autophagy and illustrate if the effects on LC3 are due to an 
increase in autophagic flux or a decrease in mitochondrial clearance. The 
amount of specific proteins in the INS-1 cells was estimated with Western blot 
using anti-LC3 monoclonal antibodies, anti-p62 monoclonal antibodies, and anti-
β-actin monoclonal antibodies. The LC3 and p62 data were then normalized to 
actin. 
Cells treated with varying concentrations of UCH-L1 inhibitor did not vary 
in the amount of LC3 present when bafilomycin was absent. Increasing the 
treatment time with bafilomycin increased the amount of LC3 present in a cell. 
Cells treated with bafilomycin for three hours showed a 10-20 fold increase in 
LC3 present, and cells in the six hour treatment groups showed a 30-50 fold 
increase in LC3. These findings were present throughout all three UCH-L1 
conditions.  
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Another measurement taken was p62, which was also normalized to actin. 
p62 is also a mitochondrial control for  autophagy. However the same results 
seen for the autophagy marker LC3 were not seen for p62. There was no pattern 
of increasing or decreasing amount of p62 when comparing the protein amount 
within UCH-L1 inhibitor groups. However, comparing p62 in each UCH-L1 
inhibitor group treated with six hours of bafilomycin, p62 increased slightly with 
increasing concentrations of UCH-L1 inhibitor. This follows a similar pattern to 
LC3-II. 
 
 
Figure 13 – INS-1 Western blots. 
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Figure 14 – Amount of LC3 measured on INS-1 Western blots. 
 
Figure 15 – Amount of p62 measured on INS-1 Western blots. 
 
 
Neurons were harvested from mouse hippocampi, plated and cultured in 
12-well plates. The neurons in vitro for 14 days were more confluent and there 
was more differentiation present (i.e., there were more glia). Both groups of 
neurons were treated with UCH-L1 inhibitor for 24 hours at concentrations of 0 
µM, 1 µM, or 10 µM. Each of these groups was then treated with bafilomycin for 
0 hours or 4 hours before harvesting the cells for western blots. The amount of 
specific proteins in both of the neurons was estimated by Western blot using anti-
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LC3 monoclonal antibodies, anti-p62 monoclonal antibodies, and anti-β-actin 
monoclonal antibodies. The LC3 and p62 data were then normalized to actin.  
Cells treated with varying concentrations of UCH-L1 inhibitor did not vary 
in the amount of LC3 present when bafilomycin was not used. Increasing the 
treatment time with bafilomycin increased the amount of LC3 present in a cell. 
Older neurons treated with bafilomycin for four hours showed a 1-2.5 fold 
increase in LC3 present, and younger neurons showed a .3-1.5 fold increase in 
LC3. These findings were present throughout all three UCH-L1 conditions. The 
amount of p62 did not follow the same pattern as LC3 in the neurons. For the 
older neurons, the amount of p62 increased when the cells were treated with 
bafilomycin in the groups treated with 1 µM UCH-L1 inhibitor and no UCH-L1 
inhibitor. However, the amount of p62 decreased in the presence of bafilomycin 
in the group treated with 10 µM UCH-L1 inhibitor.  With the younger neurons, p62 
increased in the presence of bafilomycin in the group not treated with UCH-L1 
inhibitor. However, in the groups treated with UCH-L1 inhibitor, p62 was 
increased in the presence of bafilomycin.  
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Figure 16 – Western blots with neuron trial 1 on the left and neuron trial 2 on the right.  
 
 
 
 
   
Figure 17 – Amount of LC3-II measured in neuron trial 1 Western blots.  
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Figure 18 – Amount of p62 measured in neuron trial 1 Western blots.  
 
 
 
 
 
  
Figure 19 - Amount of LC3-II measured in neuron trial 2 Western blots. 
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Figure 20 - Amount of p62 measured in neuron trial 2 Western blots. 
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Figure 21 – LC3-GFP INS-1 Western blots. 
 
 
When the data normalized to the 0-0 condition are organized according to 
bafilomycin groups, as in Figure 18, it is much easier to see that there is an 
increase in GFP when cells are treated with an increasing amount of UCH-L1 
inhibitor and under the same bafilomycin treatment conditions. When the data is 
normalized to the 0 hours bafilomycin in each UCH-L1 inhibitor group, there is 
also a noticeable trend of increased free GFP with an increase in time exposed 
to bafilomycin. 
 
  
Figure 22 - Amount of free GFP measured in LC3-GFP INS-1 Western blots. 
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Figure 23 – Amount of free GFP in LC3-GFP INS-1 Western blots compared among UCH-L1 
inhibitor groups. 
 
 
 
 
Figure 24 – Amount of free GFP in LC3-GFP INS-1 Western blots compared among bafilomycin 
groups.   
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DISCUSSION 
 
Celigo Analysis   
The Celigo® data was extremely valuable in paving the way for Western 
blot protocol and analysis. The Celigo® results from Figure 9 demonstrate that 
the SH-SY5Y cells labeled with MitoTracker Green have less fluorescence when 
treated with UCH-L1 inhibitor and when treated with rotenone. MitoTracker 
Green is a green-fluorescent mitochondrial dye that covalently binds free 
sulfhydryls in the mitochondria, regardless of the membrane potential the 
mitochondria possess. Therefore, MitoTracker Green is an indirect measurement 
of mitochondrial mass. Less MitoTracker Green corresponds to less average 
fluorescence, which translates to a decrease in mitochondrial mass. Rotenone is 
a pharmacological agent that interferes with the mitochondrial electron transport 
chain by inhibiting complex one. This damages mitochondria by causing reactive 
oxygen species (ROS) to form (Mizushima et al, 2010). When treated with 
rotenone, the SH-SY5Y cells in Figure 9 show a similar pattern as the cells 
treated with UCH-L1 treatment alone. Celigo results from Figure 10 do not show 
the same pattern of results as Figure 9. However, the results from Figure 10 are 
less consequential because the error bars are larger and the data is less 
significant.  
The DsRed SH-SY5Y cells were treated in the same fashion as the cells 
with MitoTracker Green, with both rotenone and UCH-L1 results. However, the 
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results obtained from the DsRed cells were unlike the MitoTracker Green data. 
DsRed is another proxy measurement for mitochondrial mass, but unlike 
MitoTracker Green, it is not a stain. DsRed is a mammalian subcellular 
localization expression vector with the mitochondrial targeting sequence fused to 
the end of the DsRed vector (Las et al, 2011). The DsRed SH-SY5Y cells treated 
with UCH-L1 inhibitor show an increase in average fluorescence intensity, while 
the opposite occurred in cells that were administered MitoTracker Green. The 
DsRed cells treated with rotenone alone show an increase in average 
fluorescence intensity, which is also an opposite trend that occurs from the 
MitoTracker Green cells.  
Although both DsRed and MitoTracker Green represent mitochondrial 
mass, different trends occur when the two groups of cells with these markers are 
pharmacologically treated. This may be due to the fact that DsRed is a protein 
and MitoTracker Green is a dye. It may also be suggestive of the possibility that 
UCH-L1 inhibitor acts on DsRed in a transcriptional or translational level, 
resulting in an increase in DsRed protein and average fluorescence intensity.  
With both forms of fluorescence measurements, a decrease in 
fluorescence intensity represents a decrease in mitochondrial mass. This 
decrease in mitochondrial mass may be due to an increase in autophagic flux, 
which would lower the amount of mitochondria in each cell. In Figure 9, for 
instance, the average fluorescence intensity per cell decreases when cells are 
treated with UCH-L1 inhibitor. This suggests that UCH-L1 plays a role in 
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suppressing autophagy, and either autophagic flux or mitochondrial clearance 
increases when UCH-L1 is inhibited. Treating the MitoTracker Green SH-SY5Y 
cells with rotenone leads to a significant decrease in fluorescence, whether the 
cells are treated with rotenone alone or in the presence of 10 µM of UCH-L1 
inhibitor. Damaging the mitochondria with rotenone seems to increase either 
autophagic flux or mitochondrial clearance.  
Adding UCH-L1 inhibitor to DsRed SH-SY5Y cells correlates with a 
statistically significant increase in fluorescence intensity. This may be due to a 
decrease in autophagic flux, which would mean UCH-L1 increases autophagic 
flux or decreases mitochondrial clearance. While this seems contrary to the 
previous proposal describing the actions of UCH-L1, perhaps the inhibitor 
suppresses different functions of UCH-L1 when treating DsRed cells than 
MitoTracker Green cells. For instance, according to Figures 10 and 11, UCH-L1 
may act to increase AP formation or decrease autophagic flux. Figure 6 
illustrates that UCH-L1 functions via conjugation of ubiquitin chains and through 
hydrolysis of ubiquitin. The ubiquitin action of UCH-L1 may also be affected 
differently in cells treated with MitoTracker Green versus cells expressing DsRed.  
Another variation between DsRed and MitoTracker Green cells is that 
fluorescence is increased in rotenone-treated DsRed cells, while it fluorescence 
is decreased under the same conditions in MitoTracker Green cells. This may 
also be due to the different affects of DsRed and MitoTracker Green on SH-
SY5Y cells as well. 
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When DsRed cells were treated with bafilomycin and UCH-L1 inhibitor, the 
pattern differed as well. While the cells treated with UCH-L1 inhibitor alone 
showed a similar rise in fluorescence, so did the cells treated with bafilomycin in 
conjunction with UCH-L1 inhibitor. Bafilomycin inhibits lysosomal activity, which 
in turn suppresses autophagy. This increases the amount of mitochondria 
present, thereby increasing fluorescence. The findings show that there is no 
significant difference between the DMSO group with bafilomycin and the DMSO 
group without bafilomycin treatment, indicating that the bafilomycin alone did not 
have an effect on the cells, or that DsRed acts to decrease autophagy in cells.  
 
 Western Blot Analysis   
After analyzing the Celigo® data, I decided to pursue further research in 
UCH-L1 function. The Western blot results of cells treated with UCH-L1 inhibitor 
were more consistent in the way of autophagy. For instance, the INS-1 cells 
demonstrate that there is not a large difference in the amount of LC3-II among 
varying concentrations of UCH-L1 inhibitor alone, which are the conditions 
Cartier et al tested. It is not surprising, then, that his study found no variations in 
autophagy among these groups. However, with an increasing amount of 
bafilomycin exposure on these same cells, there is an increase in LC3-II, and 
repeating this experiment in neurons at different stages in development showed 
the same pattern. The use of a lysosomal inhibitor, bafilomycin, shows that the 
increase in LC3-II is in fact due to an increase in autophagic flux and this 
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suggests the Celigo® data was not due to a decrease in mitochondrial clearance. 
The protein p62 was also measured in INS-1 cells and neurons as a control. I 
expected that the amount of mitochondrial p62 in response to UCH-L1 inhibitor 
and bafilomycin to follow a pattern similar to the LC3-II results. While it is present 
in some of the blots, it is not as pronounced, and therefore, will not be discussed 
in depth. If time allowed, another loading control protein would be tested, such as 
tubulin, to substantiate the LC3-II results (Mizushima et al, 2010). The LC3-II 
results are slightly skewed because they were normalized to actin. Actin is 
commonly used as a loading control, but as seen in Figures 13 and 16, the actin 
concentrations vary depending on the treatment conditions. Therefore, LC3-II 
measurements should also be normalized to another control in future 
experiments.  
LC3-GFP cells were also exposed to the same conditions as the INS-1 
cells and the neurons. Free GFP was measured in lieu of LC3-II in order to 
measure autophagic activity (Mizushima et al, 2010). With increasing 
concentrations of bafilomycin, the differences between the untreated and 10 µM 
UCH-L1 inhibitor groups was exaggerated, showing in increase in free GFP. 
Collectively these experiments suggest that in INS-1, SH-SY5Y and primary 
neurons chemical inhibition of UCH-L1 leads to an increase in autophagic flux. 
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Conclusion  
To summarize, my study illustrates that while the Cartier et al study had a 
concrete launching point, the experimental design was not properly planned out, 
and as a result, the conclusions drawn regarding autophagy were incorrect. 
Assessing proxy measurements of mitochondrial mass, such as MitoTracker 
Green and DsRed, gave conflicting readouts that have multiple potential 
explanations that will require future study to decipher.   Measurements of 
autophagic flux produced a much more consistent readout.  Protein 
measurement of LC3-II and free GFP derived from LC3-GFP illustrate that 
autophagic flux is upregulated in the presence of UCH-L1 inhibition. While further 
studies should be done to elaborate on the findings, these results show that 
autophagy is a key component of UCH-L1 activity and this may lead to future 
targets for PD treatment.  
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